Pharmacoeconomic aspects of memantine (Ebixa®) in the treatment of Alzheimer’s disease

References

• Wimo A, Winblad B, Aguero Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disonl. 17,63–67 (2003).
   PubMed Web of Science ®Google Scholar
• Wimo A, Morthenson Eldof C. OECD case study on dementia. Sweden. Stockholm: Stiftelsen Aldrecentrum, Stockholm och Socialdepartementet, Stockholm. Stockholm Gerontology Research Center and the Ministry of Social Affairs, Stockholm, Sweden. (2003).
   Google Scholar
• Folstein ME, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. j PFhiatr Res. 12,189–198 (1975).
   Google Scholar
• Winblad B, Wimo A, Mobius HJ, Fox JM, Fratiglioni L. Severe dementia: a common condition entailing high costs at individual and societal levels. Int. j Getiatr Psych. 14, 911–914 (1999).
   Google Scholar
• Fratiglioni L, Viitanen M, Backman L, Sandman PO, Winblad B. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 11 (Suppl. 1), 29–36 (1992).
   Google Scholar
• Grafstrom M, Winblad B. Family burden in the care of the demented and nondemented elderly — a longitudinal study. Alzheimer Dis. Assoc. Disonl 9, 78–86 (1995).
   PubMedGoogle Scholar
• Wimo A, Winblad B, Grafstrom M. The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. Int.j Geriat. Psychiatry 14, 338–347 (1999).
   Google Scholar
• Grafstrom M, Fratiglioni L, Sandman PO, Winblad B. Health and social consequences for relatives of demented and nondemented elderly. A population-based study." Gun. Epidemiol. 45,861-870 (1992).
   Google Scholar
• Jansson W, Grafstrom M, Winblad B. Daughters and sons as caregivers for their demented and nondemented elderly parents. A part of a population-based study carried out in Sweden. Land. j Soc. Med. 25,289–295 (1997).
   Google Scholar
• Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAIVIA 282,2215–2219 (1999).
   PubMed Web of Science ®Google Scholar
• Wimo A, von Strauss E, Nordberg G, Johannsson L. Time spent on informal andformal care giving for persons with dementia in Sweden. Health Pol. 61, 255–268 (2002).
   PubMed Web of Science ®Google Scholar
• Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CM4J159, 457–465 (1998).
   Google Scholar
• Stommel M, Collins CE, Given BA. The costs of family contributions to the care of persons with dementia. Gerontologist 34, 199–205 (1994).
   Google Scholar
• Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin. Pharmacol. Ther. 58,228–236 (1995).
   PubMed Web of Science ®Google Scholar
• Cavallo MC, Fattore G. The economic and social burden of Alzheimer's disease on families in the Lombardy region of Italy. Alzheimer Dis. Assoc. Disord 11,184–190 (1997).
   PubMed Web of Science ®Google Scholar
• Rice DP, Fox PJ, Max W et al The economic burden of Alzheimer's disease care. Health Aft: 12,164–176 (1993).
   PubMed Web of Science ®Google Scholar
• Albert SM, Sano M, Bell K, Merchant C, Small S, Stem Y. Hourly care received by people with Alzheimer's disease: results from an urban, community survey. Gerontologist 38,704–714 (1998).
   PubMedGoogle Scholar
• Novella J, Ankri J, Morrone I et al Evaluation of the quality of life in dementia with a generic quality of life questionnaire: the Duke Health Profile. Dement. Geriatr Cog. Disord 12,158–166 (2001).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med. Decis. Waking-20, 413–422 (2000).
   Google Scholar
• Neumann PJ, Kuntz KM, Leon J etal Health utilities in Alzheimer's disease: a cross—sectional study of patients and caregivers. Med. Cate 37,27–32 (1999).
   Google Scholar
• Patrick DL, Starks HE, Cain KC, Uhlmann RF, Pearlman RA. Measuring preferences for health states worse than death. Med. Decis. Making14, 9–18 (1994).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B. Pharmacoeconomics of dementia: impact of cholineesterase inhibitors. In: Alzheimer 's Disease and Related Disorders Annual 2002. Gauthier S, Cummings J (Eds). Martin Dunitz, London, UK (2002).
   Google Scholar
• Wimo A, Jonsson L. Demenssjukdomarnas samhällskostnader. The societal costs of dementia. Stockholm, Sweden. Socialstyrelsen. The National Board of Wealth and Healthcare (2001).
   Google Scholar
• Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist 43,158–164 (2003).
   PubMedGoogle Scholar
• Katz S, Ford AB, Moskowitz RB, Jackson BA, Jaffe MW. A standardized measure of biological and psychosocial function. JA/V/A 185,914–919 (1963).
   Google Scholar
• Wimo A, Karlsson G, Nordberg A, Winblad B. Treatment of Alzheimer's disease with tacrine: a cost—analysis model. Alzheimer Dis. Assoc. Disord 11,191–200 (1997).
   PubMed Web of Science ®Google Scholar
• Wimo A, Witthaus E, Rother M, Winblad B. Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin. Then 20, 552–566 (1998).
   PubMed Web of Science ®Google Scholar
• Leung GM, Yeung RY, Chi I, Chu LW The economics of Alzheimer's disease. Dement. Geriat. Cog. Disoml 15,34–43 (2003).
   PubMedGoogle Scholar
• Finkel S. The significance of the behavioral and psychological symptoms of dementia. Clinician 16,33–42 (1998).
   Google Scholar
• Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. Neumsci. 8,565–571 (1996).
   Google Scholar
• Danysz W, Parsons CG, Möbius HJ, Stöffier A, Quack G. Neuroprotection and symptomatological action of memantine relevant for Alzheimer's disease — an unified hypothesis on the mechanism of action. Neurotox. Res. 2,85–98 (2000).
   Google Scholar
• Parsons CG, Danysz W Quack G. Memantine is a clinically well-tolerated NMDA receptor antagonist — a review of preclinical data. Neuropharmacology 38, 735–767 (1999).
   PubMed Web of Science ®Google Scholar
• Wenk GL, Quack G, Moebius HJ, Danysz W No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 66,1079–1083 (2000).
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study. Benefit and efficacy in severely demented patients during treatment with memantine. Int.j Geriatn PTchiatry14,135–146 (1999).
   Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl. Med 348,1333–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Stöffier A, Wirth Y, Möbius H. Effects of long-term treatment with memantine, a NMDA antagonist, on costs associated with advanced Alzheimer's disease: results of a 28-week, randomized, double-blind, placebo-controlled study. 8th International Conference on Alzheimer 's Disease and Related Disorders, Stockholm Sweden. (2002).
   Google Scholar
• Wimo A, Winblad B, Engedal K etal An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement. Geriat. Cog. Disord 15,44–54 (2003).
   Google Scholar
• Wimo A, Winblad B, Stöffier A, Wirth Y, Möbius HJ. Resource utilization and cost analysis of memantine in patients with moderate-to-severe Alzheimer's disease. PharmacoEconomics 21,327–340 (2003).
   Google Scholar
• Briggs A. Economic evaluation and clinical trials: size matters. BE Med. 1321, 1362–1363 (2000).
   Google Scholar
• Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int. J Geriatn PTchiatry13, 445–453 (1998).
   Google Scholar
• O'Brien BJ, Goeree R, Hux M etal Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. A117. Geriatn Soc. 47,570-578 (1999).
   Google Scholar
• Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin. Thec 21,1230–1240 (1999).
   Google Scholar
• Neumann PJ, Hermann RC, Kuntz KM et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52, 1138–1145 (1999).
   PubMed Web of Science ®Google Scholar
• Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement.
   Google Scholar
• Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
   Google Scholar
• Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology57, 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild-to-moderate Alzheimer's disease in the Netherlands. Dement. Geriat. Cog. Disoal 14,84–89 (2002).
   Google Scholar
• Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. Assessment of Health Economics in Alzheimer's disease (AHEAD). Treatment with galantamine in Sweden. PharmacoEconomics 20,629–637 (2002).
   Google Scholar
• Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G. Economic evaluation of galantamine in the treatment of mild-to-moderate Alzheimer's disease in the United States. Clia Then 25, 1806–1825 (2003).
   Google Scholar
• Reisberg B, Ferris SH, Moebius HJ, Stöffier A, Schmitt FA, Doody R. Long-term treatment with the NMDA antagonist memantine: results of a 24 week, open label extension, ICAD, Stockholm, Sweden, Neumbiology Age. 23, (2002).
   Google Scholar
• SiWimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the resource utilization and caregiver time in Antidementia drug trials — a quantitative battery. In: The Health Economics of Dementia Wimo A, Jonsson B, Karlsson G, Winblad B (Eds). John Wiley & Sons, London, UK (1998).
   Google Scholar
• Wimo A, von Strauss E, Nordberg G, Sassi F, Johansson L. Time spent on informal and formal care giving for persons with dementia in Sweden. Health Pal 61, 255–268 (2002).
   PubMed Web of Science ®Google Scholar
• Wimo A, Johansson L, von Strauss E, Nordberg G. Formal and informal home care to Swedish demented patients, an application of RUD (Resource Utilization in Dementia. Int. Psychogeriatrics11\(Suppl. 1), 197 (1999).
   Google Scholar
• Wimo A, Winblad B. Resource utilisation in dementia: RUD Lite. Brain Aging- 3, 48–59 (2003).
   Google Scholar
• Wimo A, Nordberg G, Jansson W Grafstrom M. Assessment of informal services to demented people with the RUD instrument. Int. J Geriat. Psych. 15, 969–971 (2000).
   Google Scholar
• Winblad B, Engedal K, Soininen H et al A 1-year, randomized, placebo-controlled study of donepezil in patients with mild-to-moderate AD. Aiumlogy 57,489–495 (2001).
   Google Scholar
• Reisberg B, Franssen E, Souren LE, Kenowsky S, Auer S. Severity scales. In: The Health Economics of Dementia. Wimo A, Jonsson B, Karlsson G, Winblad B (Eds). John Wiley & Sons, London, UK (1998).
   Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neural 56,303–308 (1999).
   PubMed Web of Science ®Google Scholar